Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention American College of Obstetricians & Gynecologists, the most common co-covered peer. The tracked stories average 2 original sources each. Zoë Armstrong appears in 1 tracked Biotech story from September 6, 2026.
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention American College of Obstetricians & Gynecologists, the most common co-covered peer. The tracked stories average 2 original sources each. Zoë Armstrong appears in 1 tracked Biotech story from September 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zoë Armstrong. Shared-story counts are live from our verified record — not editorial picks.
Non-invasive endometriosis tests advancing abroad highlight a diagnostic market serving 1 in 10 women, but U.S. availability lags and experts warn current tools are not complete solutions. For biotech and pharma, the opportunity lies in validating biomarkers or imaging that can beat surgical confirmation on sensitivity and cost. Regulatory clearance and clinical trial evidence, not patient demand, remain the gating factors.
Zoë Armstrong is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
